Ambiotis is involved in a project funded by the European Union’s Horizon 2020 research and Innovation programme under grant agreement N°779295.
This project aims at optimizing the diagnostic, classification and clinical management of patients with auto–inflammatory disorders (AID). A wide spectrum of innovative techniques (multiomics, bioinformatic and mathematical modelling …) will be used to characterize potential pathogenic pathways at different steps of the inflammatory process and identify biomarkers in patient samples. Ambiotis will be in charge of assessing resolution markers by metabololipidomics.